CGON: Multiplikator rega marang pendapatan CG Oncology Therapeutics

Logo korporat perusahaan CG Oncology Inc (CGON)

The revenue valuation metric illustrates the dynamics of CG Oncology, Inc. (CGON), where 1225.50 is the current value of the indicator. The business faces strict FDA oversight and colossal R&D expenditures. Meanwhile, unique oncolytic viruses enable the effective destruction of bladder tumors. The transition to mass sales will create operational leverage, which will significantly optimize historical development costs.

CGON: Rasio rega marang pendapatan CG Oncology Corp 14.11.2024 - 17.11.2026

Rincian analitis perusahaan cgoncology.com (CGON)

Analisis fundamental perusahaan:CGON - CG Oncology Inc
Produk sing diprodhuksi CG Oncology, Inc.

Investors in CG Oncology, Inc. (CGON) must understand the business's market value relative to its ability to generate cash flow. This metric is calculated as the ratio of the issuer's total market capitalization to annual sales, and an analysis of the price-to-sales ratio allows for an assessment of the uniqueness premium for oncolytic therapies amid inelastic demand for cancer treatment.

Pesaing CG Oncology, Inc.

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rega marang dodolan UroGen Pharma Ltd.|BCAX: Multiplikator P/S|PSNL - Koefisien rega marang pendapatan|ERAS (Erasca Oncology) - Multiplikator P/S|Multiplikator P/S Delcath Systems, Inc.|Rasio rega marang pendapatan ymabs.com (YMAB)|Rasio rega marang pendapatan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Kapitalisasi marang pendapatan|Accuray Inc. (ARAY) - Rega marang dodolan|SELLAS Life Sciences Group, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Rasio rega marang pendapatan|HURA - Koefisien rega marang pendapatan|TARA (Protara Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Fate Therapeutics Inc|Multiplikator P/S WHWK|Multiplikator P/S TScan Therapeutics Inc (TCRX)|Rasio rega marang pendapatan championsoncology.com CSBR|XBIT - Kapitalisasi marang pendapatan|CVM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (OS Therapies)|RADX: Multiplikator P/S|Artiva Biotherapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd